Quantitative measurement of Schizophrenia using Electrovestibulography.

据估计，2001年精神分裂症的成本约为18.5亿美元(占国内生产总值的0.3%，澳大利亚37000名患者每人近5万美元)。超过三分之一的费用由患者及其照顾者承担。误诊和不正确的治疗很常见。到目前为止，对精神分裂症患者的定量评估是不可能的，这使得这一工具具有潜在的无价价值。准确的诊断测试有助于患者的早期诊断、更准确的治疗计划和预防衰弱的精神疾病发作。通过能够监测药物疗效，社区可以从减少药物成本、监禁时间和加快新药开发中受益。

Schizophrenia was estimated to cost approximately $1.85billion in 2001 (0.3% of GDP and nearly $50k for each of the 37,000 Australians with the illness). Over one third of the cost is borne by sufferers and their carers. Misdiagnosis and incorrect therapy are common. To date quantitative assessment of Schizophrenics has been impossible making this tool potentially invaluable. An accurate diagnostic test could facilitate earlier diagnosis, more accurate treatment plans, and prevention of debilitating psychotic episodes for the sufferer. By being able to monitor drug efficacy the community can benefit by reduced drug costs, confinement times and hastened new drug development.